BioCentury | Dec 1, 2020
Deals
Viracta to start pivotal trial as public company following Sunesis merger, private placement
...pivotal trial of its lead therapy targeting EBV-positive lymphomas.By merging with Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS), Viracta Therapeutics Inc....
...Monday.TARGETSBtk – Bruton’s tyrosine kinaseEBV - Epstein-Barr virusPDK1 - Pyruvate dehydrogenase kinase 1 Paul Bonanos VRx-3996, chr-3996, Tractinostat Viracta Therapeutics Inc. Sunesis...
...Monday.TARGETSBtk – Bruton’s tyrosine kinaseEBV - Epstein-Barr virusPDK1 - Pyruvate dehydrogenase kinase 1 Paul Bonanos VRx-3996, chr-3996, Tractinostat Viracta Therapeutics Inc. Sunesis...